Sanofi S.A. is a French multinational pharmaceutical company headquartered in Gentilly, France, as of 2013 the world's fifth-largest by prescription sales

1. SANOFI
BECAUSE HEALTH MATTERS
By
Lakshmi Ananth
JobinThomas

2. HISTORY & LEGACY
• Founded in 1956 4pas Hoechst Fedco Pharma pvt. Limited.
• Merged with Roussel India Limited in 1997 to form Hoechst Marion Roussel Limited.
• Globally acquired Aventis in 2001 and rebranded as Sanofi (in May 2011)
Subsidiary Company Main Operation
Sanofi Pasteur (from 1996) Vaccine division
Shantha Biotechnics (from 1993) Biotech company for research in rare diseases
Genzyme (from 2011) Recombinant health care products
Chattem (from 2010) OTC products
Zentiva Generic products
Medley Contract Manufacturing
Nichi-Iko & Merial Generic products

3. Major Therapeutic Areas
• Cardiovascular Diseases
• Thrombosis
• Diabetes
• Internal Medicine
• Veterinary Medicines
• Central Nervous System
• Oncology
• Arthritis and Osteoporosis
• Consumer Health Care
Due to world-class R&D pipeline, Sanofi India has leading positions in the following major
therapeutic areas:

4. SWOT Analysis
STRENGTHS
• Fourth largest company by prescription sales
• Market leadership in vaccines with Sanofi Pasteur
• Oncology pipeline has more than 15 molecules.
• Usage of renewable energy for manufacturing site
• Very good in conducting Social Responsibilities like
tuberculosis awareness programmes, diabetes
awareness programmes etc.,
OPPURTUNITIES
• Can capture entire African Market and expansion to new
geographical areas.
• Genzyme has given its considerable presence in uncommon
diseases.
• Population growth and increase of purchasing power of
developing countries.
• Marketing agreements with leading companies in
developing and developed countries.

5. SWOT Analysis
WEAKNESS
• Employee generated lot of negative publicity for
company.
• Very small business units (Only 2 business units in Goa &
Anklaleswar).
• Patent expiry of most of blockbuster drugs (Plavix® and
Lovenox®).
• Low R&D productivity.
THREATS
• Global economic slowdown as major of company’s
revenue is based on Exports.
• Chance of losing market because of quality Issues
(Combiflam® withdrawal in May 2016).
• Stringent regulations in new drug development.
• Increase in generic competition.

6. LITERATURE & RESOURCES
• Sanofi India Official Website(http://www.sanofi.in/)
• Statement on the recall of Combiflam® batches, May 23rd 2016.
• Financial Results for the Q1, June 30, 2016.
• Zentiva International Website(http://www.zentiva.com/)
• Shantha Biotechnics Website (http://shanthabiotech.com/)
• Sanofi Genzyme Website (https://www.sanofigenzyme.com/)

7. ThankYou.!
BECAUSE HEALTH MATTERS
SANOFI